Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, Aura Biosciences, Seagen, IDEAYA, Ascentage Pharma
The ocular melanoma market is expected to grow significantly by 2034, driven by increasing disease prevalence, awareness, and the launch of innovative pipeline products, especially those addressing unmet needs in metastatic cases. Key companies like Immunocore, Delcath Systems, and Aura Biosciences are developing advanced therapies, including targeted and immunotherapies, which are revolutionizing treatment options beyond traditional radiation and surgery, despite challenges such as low disease prevalence and high treatment costs. The market size was valued at approximately $340 million in 2023.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Assertio (ASRT), a stock in the Medical sector, has significantly outperformed its peers and the sector as a whole, with a 36.4% year-to-date return compared to the sector's 1.9%. The company holds a Zacks Rank of #2 (Buy) due to improving analyst sentiment and earnings outlook. Aura Biosciences, Inc. (AURA) is another Medical stock showing strong performance this year.
Aura Biosciences, Inc. (AURA) Stock Analysis: Unpacking a 259% Potential Upside in Biotech Innovation
Aura Biosciences, Inc. (AURA) is presented as a clinical-stage biotech company with significant investment potential, offering a 259.43% upside according to analyst targets. Despite its current stock price nearing oversold territory and negative financial metrics typical of early-stage biotechs, the company's innovative virus-like drug conjugate platform and lead candidate, bel-sar, in late-stage clinical development, drive strong bullish sentiment among analysts. Investors seeking groundbreaking medical innovations and substantial returns may find AURA an appealing, though high-risk, option.
Avoiding Lag: Real-Time Signals in (AURA) Movement
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI models to provide real-time trading signals and strategies. It highlights mixed sentiment, potential choppiness, and offers specific position trading, momentum breakout, and risk hedging strategies based on different risk profiles. The analysis includes support, resistance levels, and risk-reward ratios across various time horizons.
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of "Moderate Buy" from Analysts
Aura Biosciences, Inc. (NASDAQ:AURA) has received an average "Moderate Buy" rating from six analysts, with a consensus one-year target price of $20.50. The company's shares opened at $5.75, showing a market capitalization of approximately $365 million and a negative P/E ratio. Insider selling of 35,618 shares has occurred in the past 90 days, while institutional investors hold a significant 96.75% of the stock.
Discipline and Rules-Based Execution in AURA Response
This article provides an analysis of Aura Biosciences Inc. (NASDAQ: AURA) highlighting near-term weak sentiment but mid-term strength within a broader long-term weak bias. It discusses resistance testing and an exceptional risk-reward short setup. The piece also details institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis generated by AI.
Aura Biosciences, Inc. (AURA): Investor Outlook with a Remarkable 257.93% Potential Upside
Aura Biosciences, a clinical-stage biotechnology company focused on precision therapies for solid tumors, is attracting significant investor attention due to its promising pipeline and a potential upside of 257.93%. The company's lead candidate, bel-sar, is in late-stage clinical development for ocular melanoma and early-stage trials for bladder cancer. Despite being pre-revenue with negative profitability metrics, analysts unanimously rate AURA as a "buy," with an average price target of $19.40, indicating substantial growth potential for risk-tolerant, long-term investors.
Aura Biosciences (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 16,928 Shares
Aura Biosciences (NASDAQ:AURA) insider Los Pinos Elisabet De sold 16,928 shares of the company's stock on January 20th for approximately $82,270, reducing her position by 3.57%. Following this transaction, she directly owns 457,463 shares valued at over $2.2 million. The stock traded down $0.05 to $4.97, with analysts holding a "Moderate Buy" consensus rating and a target price of $20.50.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com
Amy Elazzouzi, SVP of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 to cover tax withholding obligations related to restricted stock unit vesting. Following this automated transaction, Elazzouzi retains 84,081 shares. This news follows Evercore ISI's "Outperform" rating for Aura Biosciences and leadership changes at NovaBridge Biosciences' subsidiary, Visara.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock
Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 on January 20, 2026. This sale was a mandatory transaction to cover tax withholding obligations related to restricted stock unit vesting. Following the sale, Elazzouzi directly owns 84,081 shares of Aura Biosciences.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com
Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 on January 20, 2026. This sale was conducted to cover tax withholding obligations related to restricted stock units. In other company news, Evercore ISI resumed coverage on Aura Biosciences with an Outperform rating, and NovaBridge Biosciences announced leadership changes within its subsidiary, Visara.
Following a 29% decline over last year, recent gains may please Aura Biosciences, Inc. (NASDAQ:AURA) institutional owners
Institutional investors hold a significant 43% ownership in Aura Biosciences, Inc. (NASDAQ:AURA), indicating their influence on the company's share price. Despite a 29% decline in the stock over the past year, recent gains, including a US$40m market cap increase last week, are likely welcomed by these institutional owners. Hedge funds also hold a substantial 33% stake, suggesting active investment and a focus on short-to-medium term value creation.
WhiteFiber, T1 Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
This article highlights several stocks, including WhiteFiber Inc (WYFI), Caleres, Inc. (CAL), Aura Biosciences Inc (AURA), GoldMining Inc (GLDG), T1 Energy Inc (TE), Aimei Health Technology Co Ltd (AFJK), United Microelectronics Corp (UMC), and Sony Group Corp (SONY), that are trading lower in Thursday's pre-market session. Reasons for the declines include a convertible senior notes offering by WhiteFiber, a CFO change at Caleres, and a mixed shelf offering by T1 Energy. Despite pre-market losses for some, US stock futures were generally higher.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com
Amy Elazzouzi, SVP of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 to cover tax obligations related to restricted stock unit vesting. Following this transaction, Elazzouzi directly owns 84,081 shares. In other news, Evercore ISI resumed coverage of Aura Biosciences with an Outperform rating and NovaBridge Biosciences announced leadership changes within its subsidiary, Visara.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock
Amy Elazzouzi, SVP of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock worth $7,683 to cover tax obligations from restricted stock unit vesting. This automatic sale leaves her with 84,081 shares. In related news, Evercore ISI restarted coverage on Aura Biosciences with an Outperform rating and a $13 price target, citing its innovative cancer treatment technology, while another company, NovaBridge Biosciences, made leadership appointments for its subsidiary Visara to develop treatments for retinal diseases.
Behavioral Patterns of AURA and Institutional Flows
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA), identifying a near-term neutral sentiment and a mid-channel oscillation pattern. It highlights an exceptional risk-reward setup targeting a 21.4% gain and outlines three institutional trading strategies tailored to different risk profiles. The analysis also provides multi-timeframe signal analysis with key support and resistance levels.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com
Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 on January 20, 2026. This transaction was an automatic sale to cover tax withholding obligations related to restricted stock unit vesting. Following this, Evercore ISI resumed coverage of Aura Biosciences with an Outperform rating and a $13.00 price target, citing its innovative photosensitive payload technology for treating early-stage cancers.
(AURA) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily discusses Aura Biosciences Inc. (NASDAQ: AURA) and its movement within algorithmic entry frameworks. It highlights a weak sentiment across all horizons supporting a short bias, an exceptional risk-reward setup, and presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with detailed entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Aura Biosciences, Inc. (AURA) Stock Analysis: A Biotech With A 257% Upside Potential
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotech, is attracting significant attention for its innovative therapies targeting solid tumors, including ocular oncology and bladder cancer, using proprietary virus-like particles. Analysts show strong confidence with six buy ratings and an average target price of $19.40, indicating a potential upside of 257.27% from its current trading price of $5.43. While facing challenges typical of clinical-stage firms, such as negative EPS and free cash flow, its focus on pipeline expansion and late-stage clinical development presents a compelling long-term growth opportunity for risk-tolerant investors.
How (AURA) Movements Inform Risk Allocation Models
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI models to inform risk allocation. Key findings indicate weak sentiment across all horizons, supporting a short bias, with an exceptional 51.5:1 risk-reward short setup targeting 17.9% downside. The analysis provides specific trading strategies (Long, Breakout, Short) with entry, target, and stop loss zones based on multi-timeframe signal strength.
(AURA) Price Dynamics and Execution-Aware Positioning
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) highlighting near-term weak sentiment, a test of support, and an exceptional risk-reward setup targeting a 16.4% gain. It provides three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis. The report also offers access to real-time signals, risk-reward ratios, and mobile alerts for key levels.
(AURA) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Aura Biosciences Inc. (NASDAQ: AURA), highlighting mixed sentiment and choppy conditions across different time horizons. It outlines distinct trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies, along with support and resistance levels. The analysis emphasizes institutional tactics, risk management, and real-time signal access.
Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?
Aura Biosciences (NASDAQ:AURA) has a cash runway of about 22 months as of September 2025, with cash reserves of US$162m and a cash burn of US$89m. While this runway is somewhat reassuring, the company's cash burn rate increased by 19% in the last year, indicating growing investments that could shorten the runway. Shareholders should consider the potential for dilution if the company needs to raise more cash, given that last year's cash burn represented 25% of its market capitalization.
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
Aura Biosciences, Inc. announced that its CEO, Elisabet de los Pinos, PhD, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The company, a clinical-stage biotechnology firm, is developing precision therapies for solid tumors, with its lead candidate bel-sar in late-stage development for early choroidal melanoma. A webcast of the event will be available on the company's website.
Aura Biosciences (NASDAQ: AURA) CEO Fireside Chat at Evercore Healthcare Conf. 2025
Aura Biosciences (NASDAQ: AURA) announced that its CEO, Elisabet de los Pinos, PhD, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025, at 10:50 a.m. ET. A live webcast will be available for investors, with a replay archived for 90 days. The company, a clinical-stage biotechnology firm, specializes in precision therapies for solid tumors, aiming to preserve organ function.
Aura Biosciences, Inc. SEC 10-Q Report
Aura Biosciences, Inc. released its Q3 2025 Form 10-Q report, detailing a net loss of $26.1 million due to increased R&D expenses and clinical trial costs. The company is advancing its lead candidate, bel-sar, in a Phase 3 trial for choroidal melanoma and expanding its development into choroid metastases and bladder cancer. Aura Biosciences anticipates increased expenses as it progresses its clinical trials and research pipeline, focusing on ocular and urologic oncology.
Aura Biosciences Reports Q3 2025 Financial Results
Aura Biosciences reported its Q3 2025 financial results, focusing on clinical execution for its early choroidal melanoma and non-muscle invasive bladder cancer trials. The company anticipates completing enrollment for the Phase 3 CoMpass trial in 2026, with topline data expected in late 2027, and data from the Phase 1b/2 NMIBC trial in mid-2026. Despite a current "Neutral" rating from TipRanks' AI Analyst due to its early-stage profile, Aura Biosciences aims to transform oncology treatment with its innovative therapies.
Aura Biosciences Leans Into Research Despite Rising Losses
Aura Biosciences increased its research spending last quarter, leading to a $26.1 million loss, as it accelerates its cancer therapy pipeline and overcomes clinical trial delays. Despite rising costs, analysts remain highly optimistic, with most rating the stock a 'buy' and projecting significant upside potential due to the company's commitment to long-term innovation and clinical success. The company's focus on its Phase 3 CoMpass trial and upcoming bladder cancer study results signals confidence in its long-term strategy.
Aura Biosciences Provides Phase 3 CoMpass Trial Update: Enrollment Completion Expected in 2026 with Topline Data by Q4 2027, Highlighting Bel-sar's Potential in Bladder Cancer Treatments
Aura Biosciences anticipates completing enrollment for its Phase 3 CoMpass trial for early choroidal melanoma in 2026, with topline data expected by Q4 2027. Despite initial enrollment challenges, recent improvements and promising immune profiling data for bel-sar, suggesting its potential in bladder cancer treatments, support the company's financial stability into mid-2027. Aura reported a Q3 2025 net loss of $26.1 million but remains on track for other trials, including a Phase 1b/2 trial for NMIBC with initial data by mid-2026.
Aura Biosciences (NASDAQ: AURA) sets CoMpass topline for Q4 2027; $161.9M cash
Aura Biosciences reported Q3 2025 results, revealing $161.9 million in cash and marketable securities, sufficient to fund operations into H1 2027. The company expects to complete enrollment for its Phase 3 CoMpass trial in 2026 with topline data anticipated in Q4 2027, while initial Phase 1b/2 NMIBC clinical data is expected in mid-2026. Despite increased R&D expenses and a wider net loss, positive immune profiling data for bel-sar support its potential in cancer treatment.
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported its Q3 2025 financial results, highlighting ongoing clinical trials for bel-sar in early choroidal melanoma and non-muscle invasive bladder cancer (NMIBC). The company provided updated timelines, expecting CoMpass trial enrollment completion in 2026 and topline data in Q4 2027. Immune profiling data reinforce bel-sar's potential as a frontline therapy across the bladder cancer spectrum, with the NMIBC trial data expected mid-2026.
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported its Q3 2025 financial results and business highlights, including updated guidance for its Phase 3 CoMpass trial in early choroidal melanoma, with enrollment completion expected in 2026 and topline data in Q4 2027. The company also highlighted positive immune profiling data for bel-sar in bladder cancer, suggesting its potential as a frontline therapy, and provided updates on trials for metastases to the choroid and cancers of the ocular surface. Aura stated that its current cash and equivalents of $161.9 million are sufficient to fund operations into the first half of 2027.
Aura Biosciences Reports Q3 2025 Financial Results
Aura Biosciences reported its Q3 2025 financial results and business highlights, focusing on clinical execution for its bel-sar therapy in early choroidal melanoma and non-muscle invasive bladder cancer (NMIBC). The company expects to complete enrollment for the Phase 3 CoMpass trial in early choroidal melanoma in 2026, with topline data by late 2027, and anticipates data from the Phase 1b/2 NMIBC trial in mid-2026. Despite a "Neutral" rating from TipRanks' AI Analyst Spark due to no revenue, increasing losses, and negative cash flows, Aura aims to transform treatment paradigms for high unmet medical needs in ocular and urologic oncology.
Have Insiders Sold Aura Biosciences Shares Recently?
A recent insider transaction at Aura Biosciences shows the CTO sold US$77k worth of shares, reducing their holding by 5.8%. While there was an insider purchase last year, the total insider sales over the past year (US$679k) significantly outweighed purchases (US$343k), and insider ownership remains relatively low at 1.6%.
Aura Biosciences CTO Makes a Bold Move with Stock Sale! - TipRanks
Aura Biosciences CTO Mark Plavsic recently sold 12,169 shares valued at $77,273, a transaction that has attracted investor attention. TipRanks' AI Analyst, Spark, rates AURA as Neutral due to its early-stage biotech profile, characterized by no revenue, increasing losses, and negative cash flows, despite a solid balance sheet. The company's stock faces bearish technical indicators and speculative valuation, with recent board appointments considered a positive but not outweighing financial and market concerns.
Why (AURA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
This article from Stock Traders Daily provides an AI-driven analysis of Aura Biosciences Inc. (NASDAQ: AURA), highlighting critical price action for tactical trading. It details key findings including a potential shift in sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward short setup. The piece also outlines specific institutional trading strategies and multi-timeframe signal analyses for AURA.
Aura Biosciences Launches Public Offering Of Common Stock And Warrants
Aura Biosciences, Inc. (AURA), a clinical-stage biotech firm, announced a public offering of its common stock and related warrants. The offering includes common stock, pre-funded warrants, and common stock purchase warrants, all issued by Aura, with final terms subject to market conditions and SEC filings. On the day of the announcement, AURA's stock closed up 5.71% and was trading an additional 4.83% higher in after-hours trading.
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
Aura Biosciences, Inc. (Nasdaq: AURA) announced the launch of an underwritten public offering of its common stock and accompanying warrants, including pre-funded warrants for certain investors. The offering is subject to market conditions, with Leerink Partners, Evercore ISI, and LifeSci Capital acting as bookrunning managers. The company, a clinical-stage biotechnology firm, aims to develop precision therapies for solid tumors.
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
Aura Biosciences has reported its first-quarter 2025 financial results and business highlights, showcasing significant progress in its ocular and urologic oncology programs. The company has enrolled the first patient in its multi-dose Phase 1b/2 trial for Non-Muscle-Invasive Bladder Cancer (NMIBC) and expects initial data by year-end 2025. Additionally, the Phase 3 CoMpass trial for early-stage choroidal melanoma is advancing, with enrollment potentially completing by the end of 2025.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in three upcoming investor conferences in May 2025: the Citizens Life Sciences Conference, the H.C. Wainwright 3rd Annual BioConnect Investor Conference, and the TD Cowen 6th Annual Oncology Innovation Summit. Members of its senior management team will hold fireside chats at each event, and webcasts will be available on the company's website. The company is developing precision therapies for solid tumors, with its lead candidate bel-sar (AU-011) in late-stage development for choroidal melanoma.
Aura bids to join the bladder cancer crowd | ApexOnco - Clinical Trials news and analysis
Aura Biosciences is advancing its drug belzupacap sarotalocan into phase 1/2 trials for non-muscle invasive bladder cancer (NMIBC), aiming to carve out a share in a competitive market. This move follows promising phase 1 data, with Aura targeting both intermediate and high-risk NMIBC patients. The company faces significant competition from established players and upcoming treatments, particularly UroGen's UGN-102.
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Aura Biosciences (NASDAQ: AURA) announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). Key findings include clinical complete responses in 4 out of 5 low-grade disease patients and visual tumor shrinkage in 2 out of 3 high-grade disease patients, with a favorable safety profile. The company is preparing for a Phase 2 trial to further evaluate bel-sar's clinical activity and durability of response, highlighting its potential as a transformative cancer treatment with rapid tumor response and immune oncology effect.
Aura Biosciences names interim CFO as Julie Feder departs
Aura Biosciences announced that its CFO, Julie Feder, will step down on October 25, 2024. Amy Elazzouzi has been appointed interim principal financial and accounting officer. The company continues to make progress with its investigational drug, bel-sar, for choroidal melanoma, with positive Phase 2 results and an ongoing Phase 3 trial.
Retina Society 2024: Aura Biosciences reports positive Phase 2 end of study results evaluating AU-011 for early-stage choroidal melanoma
Aura Biosciences announced positive Phase 2 end-of-study results for AU-011 (Bel-Sar) in early-stage choroidal melanoma, demonstrating 80% tumor control, 90% visual acuity preservation, and a favorable safety profile. These results suggest AU-011 could become the first vision-sparing treatment for this life-threatening ocular cancer, with a Phase 3 CoMpass trial currently enrolling patients. The FDA has provided a Special Protocol Assessment for the Phase 3 trial design.
AURA Stock Price and Chart — NASDAQ:AURA
This article provides a comprehensive overview of Aura Biosciences, Inc. (AURA) stock, including its current price, historical performance, key financial metrics, and company information. It also details upcoming earnings reports, analyst ratings, and various ETFs that hold AURA stock.
